TABLE 2.
Treatment delivery
| Age < 70 years | Age ≥ 70 years | ||
|---|---|---|---|
| N = 65 | N = 21 | P‐value | |
| Platinum agent | <.01 | ||
| Cisplatin | 49 (75.4%) | 9 (42.8%) | |
| Carboplatin | 16 (24.6%) | 12 (57.2%) | |
| No. of cycles delivered, median (range) | 5 (1–6) | 4 (1–6) | .24 |
| Initial dose reduction | 2 (3.1%) | 11 (52.3%) | <.001 |
| Discontinuation of chemotherapy | 34 (52.3%) | 16 (76.2%) | .08 |
| Reason for discontinuation | |||
| Adverse events | 18 (52.9%) | 7 (43.8%) | .78 |
| Disease progression | 14 (41.1%) | 7 (43.8%) | .38 |
| Patients' refusal | 1 (2.9%) | 2 (12.5%) | .15 |
| Conversion surgery | 1 (2.9%) | 0 (0.0%) | 1.00 |
| Cumulative dose (mg/m2), median (range) | |||
| Cisplatin | 420 (100‐600) | 400 (100–600) | .59 |
| Carboplatin | 1818 (734‐3240) | 1710 (275‐2125) | <.05 |
| Fluorouracil | 17 600 (3000‐24 000) | 14 400 (1920‐24 000) | <.03 |
| Relative dose intensity (%) | |||
| Cisplatin | 79.5 (53.7‐100.0) | 71.0 (63.0‐72.9) | .06 |
| Carboplatin | 83.4 (46.2‐100.8) | 80.0 (62.6‐100.0) | .45 |
| Fluorouracil | 81.3 (46.3‐100.8) | 78.8 (63.0‐80.4) | .10 |
| Subsequent treatment | |||
| Nivolumab | 26 (40.0%) | 8 (38.1%) | 1.00 |
| Taxane | 12 (18.5%) | 4 (19.0%) | 1.00 |
| Cetuximab | 11 (16.9%) | 2 (9.5%) | .51 |
| Others | 3 (4.6%) | 1 (4.8%) | 1.00 |